The efficacy and safety of hepatic resection (HR) to treat patients with Barcelona Clinic Liver Cancer (BCLC) stage B and C hepatocellular carcinoma (HCC) was retrospectively assessed. Background: Although guidelines from the European Association for the Study of Liver Disease and the American Association for the Study of Liver Disease do not recommend HR for treating BCLC stage B/C HCC, several Asian and European studies have come to the opposite conclusions. Methods: A consecutive sample of 1259 patients with BCLC stage B/C HCC who underwent HR (n = 908) or transarterial chemoembolization (TACE, n = 351) were included. Moreover, propensity score-matched patients were analyzed to adjust for any baseline differences. In parallel with this retrospective clinical study, the MEDLINE database was searched for studies evaluating the efficacy and safety of HR for BCLC stage B/C HCC. Results: Among our patient sample, the 90-day mortality rate in the HR group was 3.1%. HR provided a survival benefit over TACE at 1, 3, and 5 years (88% vs 81%, 62% vs 33%, and 39% vs 16%, respectively; all P < 0.001). Propensity scoring and subgroup analyses based on tumor size, tumor number, presence or absence of macrovascular invasion, and portal hypertension (PHT) also showed that HR was associated with better longterm survival than TACE. All 36 studies identified in our literature search reported that HR is associated with good long-term survival and low morbidity. Multivariate analyses revealed that alpha-fetoprotein more than or equal to 400 ng/mL, diabetes mellitus, macrovascular invasion, and PHT are independent predictors of poor prognosis in patients with BCLC stage B/C HCC. Conclusions: Our clinical and literature analyses suggest that in patients with HCC with preserved liver function, the presence of large, solitary tumors, multinodular tumors, macrovascular invasion, or PHT are not contraindications for HR.
criteria (up to 3 lesions <3 cm, <5 cm for any single lesion, no extrahepatic manifestations, no vascular invasion) 2 and who have well-preserved liver function. In such patients, the 5-year survival rate after HR exceeds 50%. [3] [4] [5] [6] Treatment outcomes for HCC patients are affected by multiple variables, including tumor burden, the Child-Pugh score of liver function reserve, and the performance status of the patient. 7 The Barcelona Clinic Liver Cancer (BCLC) classification staging system takes into account these 3 variables. 8 It links staging with treatment indications and prognostic information, such as estimated life expectancy. Studies have validated and proposed the clinical usefulness of this staging system, making it one of the most reliable for HCC. 9, 10 The BCLC staging system recommends different treatment options for each stage of the disease. According to this staging system, 8 transarterial chemoembolization (TACE) should be considered in patients with intermediate (BCLC-B) HCC and in certain patients with advanced (BCLC-C) HCC. Curative HR, in contrast, is indicated only in some patients with early-stage HCC and satisfactory liver function. The efficacy and safety of HR for treating BCLC stage B/C HCC are therefore poorly understood. Some studies [11] [12] [13] have reported that major HR for large or multinodular HCC may increase the risk of intraoperative blood loss and postoperative liver failure, leading them to advise against HR as a first-line treatment for HCC outside the Milan criteria. [11] [12] [13] Nevertheless, many hepatobiliary institutions, including our own, 14 advocate HR to treat HCC outside the Milan criteria. Given these conflicting recommendations, the efficacy and safety of HR for treating these HCC patients needs to be clarified.
In this multicenter retrospective study, we assessed the therapeutic value of HR and compared it with TACE for treating BCLC stage B/C HCC patients in the Guangxi province of China, where the population shows the highest HCC incidence rates in the world. 15, 16 To complement this clinical study, we comprehensively searched MEDLINE for studies evaluating the efficacy of HR for BCLC stage B/C HCC.
PATIENTS AND METHODS
This study was approved by the institutional review board of Guangxi Medical University, and it was conducted in accordance with the Declaration of Helsinki and current ethical guidelines. the lymph nodes and/or distant metastases were excluded on the basis of preoperative imaging results and perioperative findings.
In the HR group, HCC diagnosis was confirmed by histopathological examination of surgical samples. In the TACE group, in contrast, HCC diagnosis was confirmed by needle biopsy or by 2 types of clinical imaging (ultrasonography, computed tomography, or magnetic resonance imaging), together with a serum level of α-fetoprotein (AFP) higher than 400 ng/mL. If diagnosis based on imaging and AFP level was uncertain, needle biopsy was performed. Tumor status was assessed by ultrasonography, computed tomographic scanning, magnetic resonance imaging, and/or hepatic angiography. Vascular invasion was defined by the presence of thrombus adjacent to the tumor in the portal and hepatic vein with vague boundaries confirmed using at least 2 imaging modalities. 17 Since our centers adopted ICG-15 in 2010, ICG-15 was not applied to the patients in this study.
Definitions
In this study, clinically relevant portal hypertension (PHT) was defined as the presence of esophageal varices and/or a platelet count of less than 100 000 per μL in association with splenomegaly. BCLC stage B and stage C HCC were defined as follows. 8, 18 
BCLC Stage B
One lesion more than 5 cm in diameter; or 2 to 3 lesions, of which at least 1 is more than 3 cm in diameter; or more than 3 lesions of any diameter.
BCLC Stage C
Any tumor with radiologically evident and/or histologically proven macrovascular invasion (segmental branches, right/left and main portal vein, hepatic vein, superior mesenteric vein, inferior vena cava).
Recurrence during follow-up was defined as the appearance of a new lesion with radiologic features characteristic of HCC.
Treatment and Follow-up
Indications for HR were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy. For HCC patients without cirrhosis, 30% remnant liver volume after HR was considered adequate, whereas for those with chronic hepatitis, cirrhosis, and severe fatty liver, the remnant volume should be more than 50%. If the patient has intermediate or advanced cirrhosis and with Child-Pugh B or C liver function, HR should not be carried out. The indication for TACE was a lack of main portal vein tumor thrombus. Patients who satisfied the indications for both HR and TACE were treated by HR unless the patient requested TACE. Both techniques were performed as described. 14 Serum AFP assay, ultrasonography, and chest radiography were performed every 3 months in the first postoperative year and every 6 months in subsequent years. Postoperative enhanced computed tomography was performed every 6 months. Postoperative antiviral treatment was rarely administered.
Treatment of Recurrence
In patients who showed recurrence or resectable extrahepatic metastasis after initial treatment, HR was performed if it was judged feasible on the basis of liver function reserve and residual liver volume, which were evaluated according to the same criteria as those used at the time of initial resection. 19, 20 If this HR could not be performed because of poor liver function or other unfavorable factors, then TACE, microwave coagulation therapy, or sorafenib therapy were applied.
Statistical Analysis
All demographic and clinicopathological data had been prospectively collected in computer databases before this retrospective analysis. Differences between categorical data were analyzed using the χ 2 and Fisher exact test (2-tailed) . Continuous data were expressed as median (range). Differences between continuous data were analyzed using the Mann-Whitney U test. Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariate analysis was carried out using the Cox proportional hazards model to generate adjusted hazard ratios and 95% confidence intervals. A P value of less than 0.05 was set as the significance threshold.
To reduce bias in patient selection, propensity analysis was carried out using logistic regression to create propensity scores for HR and TACE patients in an observational database. 21, 22 Logistic regression was applied to clinical variables differing significantly between HR and TACE patients with HCC, and propensity scores were generated along a continuous range from 0 to 1. The model was then used to provide a one-to-one nearest-neighbor match between patients undergoing HR or TACE. 23, 24 For all tests, a 2-tailed P < 0.05 was considered statistically significant. All statistical analyses were performed using the SPSS 17.0 statistical package (SPSS Inc., Chicago, IL).
Comprehensive MEDLINE Review
We comprehensively searched the MEDLINE database using the following medical subject headings (MeSH): hepatocellular carcinoma or liver cancer or primary liver carcinoma and liver resection or hepatic resection or surgery. Manual searching of relevant references and review articles was also performed. Studies were included in our review if they (a) evaluated the efficacy of HR for primary BCLC stage B/C HCC, (b) were published in English, and (c) were published between January 2000 and April 2013, to ensure comparability with our retrospective clinical study. Studies evaluating HR to treat recurrent HCC or studies involving fewer than 50 patients were excluded. In the case of multiple studies based on the same population, we selected the study with the largest number of participants.
RESULTS

Characteristics of the Entire Study Population
From January 2000 to December 2007, 4535 patients with HCC from southern China were enrolled in the prospective databases of the 3 study hospitals. On the basis of the inclusion criteria, 1259 patients (28%) were enrolled in this retrospective study. Of these patients, 908 (72%) received HR, whereas 351 (28%) underwent TACE ( Fig. 1 ). HCC diagnosis was confirmed in TACE patients by needle biopsy (10.1%) or using 2 imaging techniques in conjunction with a serum level of AFP higher than 400 ng/mL (89.9%).
Baseline demographic and clinicopathological data for the 1259 patients are shown in Table 1 . Patients in the TACE group were significantly older and had larger tumor size and higher levels of alanine aminotransferase and total bilirubin (all P < 0.001). More patients in the HR group were positive for hepatitis B surface antigen (P = 0.018). There were no significant differences in sex, number of tumors, hepatitis C antibody positivity, serum AFP or albumin level, distribution of cancer stages or frequencies of diabetes mellitus (DM), macrovascular invasion, or esophageal varices (all P > 0.05). complications were assessed using the Clavien-Dindo classification. Most complications were grade I or II (Table 2) . Patients in the HR group had a significantly higher rate of postoperative complications (27%) than did patients in the TACE group (19%). The most frequent complications in HR patients were pulmonary infection (7.0%) and liver function failure (4.0%); the most frequent complications in TACE patients were liver function failure (4.6%) and puncture hematoma (4.6%).
Survival Analysis of the Entire Study Population
During a follow-up period lasting a median of 31.2 months (range, 1-120.3), 575 (63%) patients in the HR group and 285 (81%) in the TACE group died. Overall survival was significantly better in the HR group than in the TACE group (P < 0.001; Fig. 2 ). In fact, the HR group showed a survival benefit over TACE at 1 year (88% vs 81%), 3 years (62% vs 33%), and 5 years (39% vs 16%) (P < 0.001). Median survival time in the HR group was 47.4 months, compared with 23.7 months in the TACE group (P < 0.001). The 1-, 3-, and 5-year recurrence rates of patients in the HR group were 32%, 58%, and 74%. Among patients with recurrence, 83% were amenable to TACE and underwent the procedure.
Additional survival analysis was performed by including factors linked to survival, including age, sex, tumor size and number, hepatitis, serum biochemistry, DM, macrovascular invasion, esophageal varices, and treatment modality ( Table 3 ). Univariate analysis identified the following prognostic factors predicting increased risk of mortality in the total population: age 60 years or older, tumor size 10 cm or bigger, tumor number 3 or more, serum AFP 400 ng/mL or more, serum alanine aminotransferase more than 80 U/L, serum bilirubin more than 1.2 mg/dL, DM, macrovascular invasion, esophageal varices, and TACE treatment. The multivariate Cox proportional hazards model identified several independent predictors of poor prognosis (Table 4) : serum AFP 400 ng/mL or more, DM, macrovascular invasion, esophageal varices, and TACE treatment.
Characteristics and Survival Analysis of Propensity-Matched Patients
Propensity analysis based on variables associated with therapeutic strategy and long-term prognosis identified 280 matched pairs of patients from each treatment group. When only these pairs were considered, the 2 treatment arms did not show significant baseline differences in age, sex, tumor size or number, serum biochemistry, DM, macrovascular invasion, esophageal varices, or tumor staging ( Table 1 ). Comparison of long-term survival in the 2 propensitymatched groups is shown in Figure 2 . As observed in the overall study population, patients selected in the propensity-matching model who underwent HR showed significantly better long-term survival than did those who underwent TACE (P < 0.001). Overall survival of HCC patients undergoing HR and TACE was 87% and 80% (1 year), 54% and 32% (3 years), and 34% and 15% (5 years), respectively. The HR and TACE groups had similar rates for 30-day mortality (1.8% vs 2.1%, P = 0.716) and 90-day mortality (2.5% vs 3.2%, P = 0.612). However, the postoperative complication rate was significantly higher in the HR group (25%) than in the TACE group (18%; P = 0.032). The multivariate Cox proportional hazards model identified serum AFP 400 ng/mL or more, DM, macrovascular invasion, esophageal varices, and TACE treatment as mortality risk factors (Table 4 ).
Subgroup Analysis of the Entire Study Population
To explore more deeply the efficacy of HR for treating BCLC stage B/C HCC, we performed subgroup analyses on the basis of tumor size and number, as well as the presence or absence of macrovascular invasion (BCLC stage B/C) and PHT.
Subgroup Analysis by Tumor Size
Patients in each group were divided into subgroups with tumor size 10 cm or bigger or smaller than 10 cm. Among patients with tumor size 10 cm or more, HR provided better long-term survival than did TACE (P < 0.001; Fig. 3A) , and HR showed a survival benefit at 1 year (86% vs 80%), 3 years (54% vs 30%), and 5 years (34% vs 16%). Similarly, among patients with tumor size smaller than 10 cm, HR provided better long-term survival (P < 0.001; Fig. 3A ). HR showed a survival benefit at 1 year (89% vs 83%), 3 years (65% vs 37%), and 5 years (40% vs 18%). The prognosis of patients with large (≥10 cm) HCC was poorer than that of patients with smaller (<10 cm) HCC (Table 3 ).
Subgroup Analysis by Tumor Number
Patients receiving each kind of treatment were divided into subgroups with 3 or more tumors or less than 3 tumors. Among patients with 3 or more tumors, survival was significantly higher in the HR subgroup at 1 year (90% vs 59%), 3 years (52% vs 11%), and 5 years (33% vs 6%) (P < 0.001) ( Fig. 3B) . Similarly, among patients with less than 3 tumors, survival was significantly higher in the HR subgroup at 1 year (88% vs 83%), 3 years (62% vs 35%), and 5 years (39% vs 17%) (P < 0.001) ( Fig. 3B ). Patients with multinodular HCC showed poorer overall survival than those with less than 3 neoplasms (Table 3 ).
Subgroup Analysis by Macrovascular Invasion
Patients were stratified on the basis of the absence of macrovascular invasion (BCLC-B) or on its presence (BCLC-C).
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Among patients with macrovascular invasion HCC, overall survival was found to be significantly better after HR than after TACE (1 year, 81% vs 68%; 3 years, 46% vs 22%; 5 years, 20% vs 5%; P < 0.001) ( Fig. 3C) . Similarly, among patients without macrovascular invasion HCC, overall survival was better for the HR group than the TACE group (1 year, 91% vs 85%; 3 years, 67% vs 36%; 5 years, 44% vs 19%; P < 0.001) (Fig. 3C ). Patients with macrovascular invasion HCC had poorer prognosis than did those without invasion (Table 3) . 3D ). HR showed a survival benefit at 1 year (76% vs 73%), 3 years (38% vs 17%), and 5 years (16% vs 7%). Similarly, among patients without PHT, HR showed survival benefit at 1 year (91% vs 82%), 3 years (67% vs 38%), and 5 years (43% vs 20%) (P < 0.001; Fig. 3D ).
Literature Review
A total of 36 eligible studies were found to satisfy the inclusion criteria, and key demographic and clinicopathological data were extracted (Table 5 ). Studies were organized into subgroups depending on whether they involved large and/or multinodular HCC, 18, HCC with macrovascular invasion, 18, 25, 34, [53] [54] [55] [56] and HCC with PHT. 35, [57] [58] [59] Most patients in included studies were from southeast Asia, the region with the highest prevalence of HCC, and most had large and/or multiple HCC.
The majority of the studies reported a hospital mortality less than 5%. However, when HR was used to treat HCC with PHT, hospital mortality was reported to rise to 11%. 57, 58 Overall survival after HR was 70% to 80% (1 year), about 50% (3 years), and about 30% (5 years). Patients with large and/or multinodular HCC showed better long-term survival than did those with HCC with macrovascular invasion or PHT. Patients with macrovascular invasion HCC showed the worst long-term survival. 
DISCUSSION
According to the guidelines of the European Association for the Study of the Liver 60 and the American Association for the Study of Liver Disease, 8 which are based on the BCLC classification, HR is indicated only for those patients with early-stage HCC. However, some new seminars [61] [62] [63] have stated that tumor size should not be used as a selection criterion for HR if tumor location and liver function allow resection, and therefore that patients with single large HCC may be considered for HR. Nevertheless, HR is not recommended as the first-line treatment for single large, multinodular, and macrovascular invasion HCCs. 64, 65 Moreover, PHT in cirrhotic patients is considered a relative contraindication for HR according to the guidelines of European Association for the Study of the Liver/American Association for the Study of Liver Disease.
In this retrospective clinical study of a large cohort of patients from a region in which more than 90% of HCC is related to hepatitis B, we found that HR led to better overall survival than did TACE, both for the entire study population as well as for a propensity-matched subpopulation. Subgroup analyses based on tumor size and number and on the presence or absence of macrovascular invasion and PHT gave similar results. The 1-, 3-, and 5-year overall survival of our HR patients was similar to that reported by other studies identified in a comprehensive review of MEDLINE (Table 6 ). Therefore, the recommendation of the consensus of the Asian Pacific Association for the Study of the Liver, 66 the Japan Society of Hepatology, 67 and the American Hepato-Pancreato-Biliary Association 68 seems reasonable: in terms of long-term survival, HR is the best treatment for selected patients with large solitary, multinodular, or macrovascular invasion HCC. In our view, when determining the HR suitability of these patients, preoperative liver function and postoperative residual liver volume are the 2 most important criteria. As long as these parameters are adequate, we suggest that there is no absolute contraindication of HR for HCC.
HR is considered the most effective treatment for HCC, 18,69,70 but perioperative morbidity and mortality have traditionally posed significant risks. Although the postoperative complication rate in our HR group (26.8%) was significantly higher than that in the TACE group (18.5%), improvements in surgical technique and perioperative care have lowered the mortality of HR for HCC. As a result, HR performed correctly on carefully selected patients is safe and effective even for HCC patients with large and multinodular tumor burden, macrovascular invasion, and compensated liver cirrhosis. 54, 70 In fact, perioperative mortality can be zero in some centers. 71, 72 By comparison, TACE-related mortality ranges from 0% to 9.5% and is primarily the result of liver failure. 73 Our results suggest that the decision whether to perform HR should not be constrained by tumor size or number. Resection led to significantly better survival than did TACE, both for patients with small (<10 cm) HCC and those with large (≥10 cm) HCC ( Fig. 3A; both P < 0.001), even though patients with large HCC treated by either technique showed worse survival. These findings, together with those of other studies, 18, [25] [26] [27] [28] [29] [30] [32] [33] [34] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] lead us to conclude that tumor size alone should not be considered a contraindication of HR. In addition, survival was better after HR than after TACE for patients treated for multiple (≥3) HCCs and those treated for single/double (<3) HCCs ( Fig. 3B; both P < 0.001), although survival after both techniques was worse after resection for 3 or more HCCs than after resection for less than 3 HCCs ( Fig. 3B ; P = 0.109). These findings suggest that multinodularity by itself should not be considered an exclusion criterion against HR. 31, 34, 56 Our results further suggest that the decision whether to perform HR should not be determined solely by the presence or absence of macrovascular invasion in HCC. Under the BCLC classification system used in this study, such invasion is the defining difference between stage B and stage C, yet HR was associated with better survival than TACE for both stages (Fig. 3C; both P < 0.001). Nevertheless, HR was not equally effective for all patients: patients with BCLC stage B HCC showed better survival than did those with BCLC stage C cancer ( Fig. 3C ; P < 0.001). These findings are consistent with several multicenter studies 18, 25, 34, [53] [54] [55] [56] identified in our MEDLINE literature search, which reported that HR for HCC with macrovascular invasion can be performed relatively safely with lower than 5% mortality, and with long-term survival far superior to that of TACE or other therapies (Table 5 ).
In our patient population with HCC, as in most parts of China, hepatitis B virus infection is endemic and screening is not routinely performed. This may help to explain why 243 (19%) of our patients had esophageal varices (Table 1 ). Our results suggest that PHT should not by itself be an exclusion criterion for HR. In our study, HR led to better long-term survival than TACE in patients with or without PHT ( Fig. 3D; both P < 0.001), although survival after either technique was lower for patients with PHT than for those without it ( Fig. 3D ; P < 0.001). These findings are consistent with studies from Europe and Asia, which found 5-year survival to be about 50% for patients with PHT treated by HR. 35, 58, 59 While we interpret these findings to mean that PHT per se is not a contraindication to HR in patients with HCC and cirrhosis, we do emphasize the need for preoperatively assessing the likelihood that perioperative liver function and postoperative residual liver volume will be sufficient. This is particularly important for reducing the risk of hepatic mortality in patients with PHT, because these factors are associated with severe cirrhosis.
Our multivariate Cox modeling to identify prognostic factors in HCC patients came to similar conclusions as previous studies: patients with high preoperative AFP level 74, 75 and DM 76,77 had significantly worse outcomes than did other patients after HR. In contrast to previous studies, our modeling did not show large tumor size 30, 45 and multinodularity 25, 35, 40 to be poor prognostic factors. Our modeling further identified 2 other independent predictors of poor prognosis: macrovascular invasion and PHT. Our finding of macrovascular invasion as a poor prognostic predictor is supported by numerous studies outside China. 42, 47, 57 Macrovascular invasion is attributed to HCC recurrence, which is the primary cause of postoperative death. Our finding of PHT as a poor prognostic factor may reflect the high 90-day mortality among patients with PHT treated with HR (10.2%, 17/166) or TACE (6.5%, 5/77). Liver failure and varices rupture are 2 major causes of mortality in these patients. Some studies have also indicated that PHT is an independent factor related for morbidity. [78] [79] [80] One of the major limitations of our clinical study is the particular characteristics of our patient population, which shows one of the highest incidences of HCC in the world. All patients in our consecutive series had Child-Pugh class A disease. Nearly half (41%) of the patients in our study arrived with BCLC stage B/C HCC (Fig. 1) , and fully 26% had BCLC stage C disease. Nevertheless, our findings are in accord with an extensive literature search in which we identified studies conducted with diverse patient populations around the world. Therefore, we believe our results are relevant for other populations. Another limitation is that analysis involving multicentric tumors was not conducted because of the insufficiently detailed data. Further studies should do this.
Given its retrospective design, our study was probably subject to selection bias. On the contrary, the established efficacy of HR and the heterogeneity of patients with HCC that require HR or TACE make it difficult to conduct a randomized controlled trial comparing the efficacy of the 2 techniques. Therefore, we used a propensity-scoring model to verify our results obtained with the entire study population. Another limitation of our study is that the use of postoperative adjuvant treatment, such as TACE and interferon, and postrecurrence retreatment with resection or other local therapies complicated efficacy comparisons between HR and TACE. Future studies should take into account the frequently multidisciplinary approach used to improve prognosis of patients with advanced HCC.
CONCLUSIONS
In this way, our clinical and literature studies suggest that HR should be considered a fundamental part of total curative treatment of HCC. Compared to TACE, HR can provide significant survival benefit for patients with HCC involving large solitary tumors, multinodular tumors, macrovascular invasion, and PHT. It is important that such patients have at least Child-Pugh class A liver function.
